ATRA vs. PASG, IKNA, TSBX, ELUT, ALGS, TIL, GNTA, CDTX, CGTX, and CRIS
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Passage Bio (PASG), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Elutia (ELUT), Aligos Therapeutics (ALGS), Instil Bio (TIL), Genenta Science (GNTA), Cidara Therapeutics (CDTX), Cognition Therapeutics (CGTX), and Curis (CRIS). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
Passage Bio currently has a consensus price target of $9.33, indicating a potential upside of 539.27%. Atara Biotherapeutics has a consensus price target of $28.00, indicating a potential upside of 4,601.14%. Given Passage Bio's higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Passage Bio.
Atara Biotherapeutics received 382 more outperform votes than Passage Bio when rated by MarketBeat users. Likewise, 67.99% of users gave Atara Biotherapeutics an outperform vote while only 66.20% of users gave Passage Bio an outperform vote.
Passage Bio has higher earnings, but lower revenue than Atara Biotherapeutics. Passage Bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
61.6% of Passage Bio shares are owned by institutional investors. Comparatively, 88.8% of Atara Biotherapeutics shares are owned by institutional investors. 12.4% of Passage Bio shares are owned by insiders. Comparatively, 4.5% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Atara Biotherapeutics had 6 more articles in the media than Passage Bio. MarketBeat recorded 8 mentions for Atara Biotherapeutics and 2 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.73 beat Atara Biotherapeutics' score of 0.29 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.
Passage Bio has a net margin of 0.00% compared to Passage Bio's net margin of -6,390.31%. Atara Biotherapeutics' return on equity of -73.12% beat Passage Bio's return on equity.
Passage Bio has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Summary
Passage Bio beats Atara Biotherapeutics on 9 of the 17 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Atara Biotherapeutics Competitors List
Related Companies and Tools